Valuation : OmniAb, Inc.

Market Cap 630M 541M 509M 465M 869M 59.54B 872M 6.04B 2.33B 30.49B 2.36B 2.31B 97.12B P/E 2026 *
-11.9x
P/E 2027 * -15.2x
Enterprise Value 630M 541M 509M 465M 869M 59.54B 872M 6.04B 2.33B 30.49B 2.36B 2.31B 97.12B EV / Sales 2026 *
18x
EV / Sales 2027 * 14.5x
Free-Float
73.81%
Yield 2026 *
-
Yield 2027 * -
1 day-8.84%
1 week-1.14%
Current month-1.14%
1 month+40.58%
3 months+74.60%
6 months+129.10%
Current year+134.05%
1 week 4.28
Extreme 4.28
5.43
1 month 2.99
Extreme 2.99
5.43
Current year 1.35
Extreme 1.35
5.43
1 year 1.3
Extreme 1.3
5.43
3 years 1.22
Extreme 1.22
6.72
5 years 1.22
Extreme 1.22
10.5
10 years 1.22
Extreme 1.22
10.5
Manager TitleAgeSince
Chief Executive Officer 53 2022-10-31
Director of Finance/CFO 58 2022-02-28
Chief Operating Officer 51 2026-07-12
Director TitleAgeSince
Director/Board Member 59 2022-10-31
Director/Board Member 54 2022-10-31
Director/Board Member 53 2022-10-31
Date Insider Type Main position Quantity % Market Cap. Importance
8/1/26 Free

Chief Operating Officer

800,000 0.5518%
4/21/26 Exercice

Director

26,666 0.0184%
4/21/26 Exercice

Director

26,666 0.0184%
Change 5-day change 1-year change 3-year change Capi.($)
-8.84%-1.14%+153.22%-19.37% 630M
-1.16%-2.77%-2.91%+13.85% 48.41B
-0.40%+2.16%+418.57%+554.47% 45.01B
-1.42%+2.52%+42.67%+22.27% 44.07B
-1.22%-0.37%+4.82%+84.42% 40.73B
-0.96%-1.38%+15.75%+45.91% 33.21B
-0.21%+2.86% - - 17.77B
-0.35%-0.45%+21.42%+117.63% 16.5B
-1.54%-1.30%+12.16%+31.14% 14.45B
-1.65%+0.09%+75.93%+41.15% 13.77B
Average -1.78%-0.06%+82.40%+99.05% 27.46B
Weighted average by Cap. -1.01%-0.04%+89.46%+134.43%

Financials

2026 *2027 *
Net sales 34.97M 30.07M 28.28M 25.82M 48.29M 3.31B 48.44M 335M 130M 1.69B 131M 128M 5.39B 43.49M 37.4M 35.18M 32.11M 60.06M 4.11B 60.25M 417M 161M 2.11B 163M 160M 6.71B
Net income -47.61M -40.95M -38.51M -35.16M -65.75M -4.5B -65.96M -457M -177M -2.31B -179M -175M -7.35B -39.58M -34.04M -32.01M -29.22M -54.65M -3.74B -54.83M -380M -147M -1.92B -149M -145M -6.11B
Net Debt - -
Logo OmniAb, Inc.
OmniAb, Inc. licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. Central to the OmniAb platform, Biological Intelligence, powers the immune systems of its engineered transgenic animals to create optimized antibody candidates for human therapeutics. Its proprietary transgenic animals, including OmniRat, OmniChicken and OmniMouse are genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic and OmniClic are fixed or common light-chain rats and chickens, designed to facilitate the discovery of bispecific antibodies. OmniTaur provides cow-inspired antibodies with unique structural characteristics for challenging targets.
Employees
89
Date Price Change Volume
26-09-04 US$4.330 -8.84% 1,703,973
26-09-03 US$4.750 -5.75% 2,011,179
26-09-02 US$5.040 +13.51% 5,084,227
26-09-01 US$4.440 +1.37% 1,156,203
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
4.330USD
Average target price
8.400USD
Spread / Average Target
+94.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. OABI Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!